Decreased HDL-dependent paraoxonase and arylesterase enzyme activity may indicate a worse prognosis in multiple myeloma

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 22, 2014, Pages 9847-9851

  Ellidag, Hamit Yasar ^a   Aydin, Ozgur ^b   Eren, Esin ^c   Yilmaz, Necat ^a   Ergin, Merve ^d  

^a Central laboratories of Antalya Education and Research Hospital of Ministry of Health   (Turkey)

^b Maternaty and Children's Hospital   (Turkey)

^c Ataturk Hospital   (Turkey)

^d ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Free light chain; Myeloma; Oxidative stress; Paraoxonase; Prognosis

Indexed keywords

ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL, HDL; OXIDANTS; PON1 PROTEIN, HUMAN; SULFHYDRYL COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

AGED; BLOOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLISM; MORTALITY; MULTIPLE MYELOMA; NEOPLASM STAGING; OXIDATIVE STRESS; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

AGED; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL, HDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM STAGING; OXIDANTS; OXIDATIVE STRESS; PROGNOSIS; PROSPECTIVE STUDIES; SULFHYDRYL COMPOUNDS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84921527535     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.22.9847     Document Type: Article

References (37)

1. Aviram M, Rosenblat M, Bisgaier CL, et al (1998). Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest, 101, 1581-90.
2. Ayub A, Mackness MI, Arrol S, et al (1999). Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol, 19, 330-5.
3. Basnayake K, Ying WZ, Wang PX, Sanders PW (2010). Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol, 21, 1165-73.
4. Batuman V, Dreisbach AW, Cyran J (1990). Light-chain binding sites on renal brush-border membranes. Am J Physiol, 258, 1259-65.
5. Batuman V, Verroust PJ, Navar GL, et al (1998). Myeloma light chains are ligands for cubilin (gp280). Am J Physiol, 275, 246-54.
6. Blade J, Teresa CM, Fernandez de LC, Rosinol L (2010). Multiple myeloma, (symposium article). Annals of Oncology, 21, 313-9.
7. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H (2008). Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia, 22, 1485-93.
8. Durie BG, Salmon SE (1975). A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-54.
9. Eckerson HW, Wyte MC, La Du BN (1983). The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet, 35, 1126-38.
10. Ellidag HY, Bulbuller N, Eren E, et al (2013). Ischemia-modified albumin: could it be a new oxidative stress biomarker for colorectal carcinoma? Gut Liver, 7, 675-80.
11. Ellidag HY, Eren E, Aydin O, et al (2013). Ischemia modified albumin levels and oxidative stress in patients with bladder cancer. Asian Pac J Cancer Prev,14, 2759-63.
12. Ellman GL (1959). Tissue sulfhydryl groups. Arch Biochem Biophys, 82, 70-7.
13. Erel O (2004). A novel automated direct measurement method for total antioxidant capacity using a new generationmore stable ABTS radical cation. Clin Biochem, 37, 277-85.
14. Erel O (2005). A new automated colorimetric method for measuring total oxidant status. Clin Biochem, 38, 1103-11.
15. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos, 19, 100-6.
16. Geldmacher-von Mallinckrodt M, Diepgen TL, Duhme C, Hommel G (1983). A study of the polymorphism and ethnic distribution differences of human serum paraoxonase. Am J Phys Anthropol, 62, 235-41.
17. Greipp PR, San Miguel J, Durie BG, et al (2005). International staging system for multiple myeloma. J Clin Oncol, 23, 3412-20.
18. Haagen L, Brock A (1992). A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolisis of 4-nitrophenyl acetate. Eur J Clin Chem Clin Biochem, 30, 391-5.
19. Harma M, Harma M, Erel O (2003). Increased oxidative stress in patients with hydatidiform mole. Swiss MedWkly, 133, 563-6.
20. Hu ML (1994). Measurement of protein thiol groups and glutathione in plasma, Methods Enzymol, 233, 380-5.
21. Jarad G, Miner JH (2009). Update on the glomerular filtration barrier. Curr Opin Nephrol Hypertens, 18, 226-32.
22. Kyle RA, Therneau TM, Rajkumar SV, et al (2006). Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med, 354, 1362-69.
23. Levey AS, Bosch JP, Lewis JB, et al (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. modification of diet in renal disease study group. Ann Intl Med, 130, 461-70.
24. Li M, Hering-Smith KS, Simon EE, Batuman V (2008). Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol Dial Transplant, 23, 860-70.
25. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G (2008). The paradoxical relationship between serum uric acid and cardiovascular disease. Clinica Chimica Acta, 3, 921-7.
26. Mackness MI, Harty D, Bhatnagar D, et al (1991). Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis, 86, 193-9.
27. Morigi M, Macconi D, Zoja C, et al (2002). Protein overload induced NF-κB activation in proximal tubular cells requires HO through a PKC-dependent pathway. J Am Soc Nephrol, 13, 1179-89.
28. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW (1997). The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood, 89, 577-82.
29. Sanders PW, Herrera GA, Chen A, Booker BB, Galla JH (1988). Differential nephrotoxicity of low molecular weight proteins including Bence Jones proteins in the perfused rat nephron in vivo. J Clin Invest, 82, 2086-96.
30. Sengul S, Zwizinski C, Batuman V (2003). Role of MAPK pathways in light chain induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol, 284, 1245-54.
31. Sharma A, Tripathi M, Satyam A, Kumar L (2009). Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma, 50, 809-15.
32. Shi Y, Evans JE, Rock KL (2003). Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 425, 516-21.
33. Strazzullo P, Puig JG (2007). Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis, 17, 409-14.
34. Stringer S, Basnayake K, Hutchison C, Cockwell P (2011). Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney), review article. Bone Marrow Res, 2011, 493697.
35. von Meyenfeldt M (2005). Cancer-associated malnutrition: an introduction. Eur J Oncol Nurs, 9, 35-8.
36. Wlodek L (2002). Beneficial and harmful effects of thiols. Pol J Pharmacol, 54, 215-23.
37. Yilmaz N (2012). Relationship between paraoxonase and homocystein: crossroads of oxidative disease. Arch Med Sci, 8, 138-53.